These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 37093346)

  • 1. MYD88
    Qin Y; Qiu T; Xie Z; Chen X; Liu P; Yang J; He X; Gui L; Zhou S; Jiang H; Zhang C; Yang S; Tang L; Shi Y
    J Cancer Res Clin Oncol; 2023 Sep; 149(11):8483-8494. PubMed ID: 37093346
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical significance of MYD88 non-L265P mutations in diffuse large B-cell lymphoma.
    Xie J; Shen X; Shi Q; Yi H; Ouyang B; Zhang Z; Gu Y; Dong L
    Hematol Oncol; 2022 Dec; 40(5):885-893. PubMed ID: 36053490
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Deciphering the Prognostic Significance of MYD88 and CD79B Mutations in Diffuse Large B-Cell Lymphoma: Insights into Treatment Outcomes.
    Xie Z; Qin Y; Chen X; Yang S; Yang J; Gui L; Liu P; He X; Zhou S; Zhang C; Tang L; Shi Y
    Target Oncol; 2024 May; 19(3):383-400. PubMed ID: 38643457
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MYD88 expression and L265P mutation in diffuse large B-cell lymphoma.
    Choi JW; Kim Y; Lee JH; Kim YS
    Hum Pathol; 2013 Jul; 44(7):1375-81. PubMed ID: 23380077
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biological and Clinical Relevance of Associated Genomic Alterations in MYD88 L265P and non-L265P-Mutated Diffuse Large B-Cell Lymphoma: Analysis of 361 Cases.
    Dubois S; Viailly PJ; Bohers E; Bertrand P; Ruminy P; Marchand V; Maingonnat C; Mareschal S; Picquenot JM; Penther D; Jais JP; Tesson B; Peyrouze P; Figeac M; Desmots F; Fest T; Haioun C; Lamy T; Copie-Bergman C; Fabiani B; Delarue R; Peyrade F; André M; Ketterer N; Leroy K; Salles G; Molina TJ; Tilly H; Jardin F
    Clin Cancer Res; 2017 May; 23(9):2232-2244. PubMed ID: 27923841
    [No Abstract]   [Full Text] [Related]  

  • 6. MYD88 L265P Mutations, But No Other Variants, Identify a Subpopulation of DLBCL Patients of Activated B-cell Origin, Extranodal Involvement, and Poor Outcome.
    Rovira J; Karube K; Valera A; Colomer D; Enjuanes A; Colomo L; Martínez-Trillos A; Giné E; Dlouhy I; Magnano L; Delgado J; Martínez A; Villamor N; Campo E; López-Guillermo A
    Clin Cancer Res; 2016 Jun; 22(11):2755-64. PubMed ID: 26792260
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinicopathologic significance of MYD88 L265P mutation in diffuse large B-cell lymphoma: a meta-analysis.
    Lee JH; Jeong H; Choi JW; Oh H; Kim YS
    Sci Rep; 2017 May; 7(1):1785. PubMed ID: 28496180
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinicopathological features of 49 primary gastrointestinal diffuse large B-cell lymphoma cases; comparison with location, cell-of-origin, and frequency of MYD88 L265P.
    Nagakita K; Takata K; Taniguchi K; Miyata-Takata T; Sato Y; Tari A; Ohnishi N; Noujima-Harada M; Omote S; Nakamura N; Iwamuro M; Maeda Y; Okada H; Tanimoto M; Yoshino T
    Pathol Int; 2016 Aug; 66(8):444-52. PubMed ID: 27439595
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MYD88 L265P mutation detected by digital PCR as a prognostic factor in patients with diffuse large B-cell lymphoma in rituximab era.
    Nishimura N; Takeuchi K; Asaka R; Tuyama N; Inoue N; Kusano Y; Mishima Y; Yokoyama M; Terui Y
    Leuk Res; 2020 Oct; 97():106426. PubMed ID: 32781214
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lack of a Prognostic Impact of the MyD88 L265P Mutation for Diffuse Large B Cell Lymphoma Patients Undergoing Autologous Stem Cell Transplantation.
    Lee YS; Liu J; Fricano KA; Webb EM; Toolsie DR; Jones S; Rhoads JA; Vij R; Cashen AF; Abboud CN; Westervelt P; Bartlett NL; Dipersio JF; Kreisel FH; Lim KH
    Biol Blood Marrow Transplant; 2017 Dec; 23(12):2199-2204. PubMed ID: 28847710
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Morphologic Patterns and the Correlation With MYD88 L265P, CD79B Mutations in Primary Adrenal Diffuse Large B-Cell Lymphoma.
    Chen Z; Zou Y; Liu W; Guan P; Tao Q; Xiang C; Zhang W; Ye Y; Yan J; Zhao S
    Am J Surg Pathol; 2020 Apr; 44(4):444-455. PubMed ID: 31609782
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DLBCL with amplification of JAK2/PD-L2 exhibits PMBCL-like CNA pattern and worse clinical outcome resembling those with MYD88 L265P mutation.
    Xue X; Huang W; Qiu T; Guo L; Ying J; Lv N
    BMC Cancer; 2020 Aug; 20(1):816. PubMed ID: 32854650
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Prevalence of MYD88 L265P and TNFAIP3 Mutations and Their Correlations with Clinico-Hematological Profile in Egyptian Patients with Diffuse Large B Cell Lymphoma.
    Elbaz O; Shaat RM; Abd El Ghaffar HA; Shamaa S; Abdel-Masseih HM; Anber N; Mortada MI
    Asian Pac J Cancer Prev; 2023 Jul; 24(7):2485-2491. PubMed ID: 37505783
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The importance of Myd88 L265P mutation, clinical and immunohistochemical prognostic factors for the survival of patients with diffuse large B-cell non-Hodgkin lymphoma treated by immunochemotherapy in southeast Serbia.
    Tadic L; Marjanovic G; Macukanovic-Golubovic L; Krstic M; Jevtovic-Stoimenov T; Kostov M; Smelcerovic Z; Stojanovic M
    J BUON; 2016; 21(5):1259-1267. PubMed ID: 27837631
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinicopathologic significance of MYD88 L265P mutation and expression of TLR4 and P-STAT3 in primary central nervous system diffuse large B-cell lymphomas.
    Tang D; Su W; Wang X; Chu Z; Zhang L; Zhou J; Zhang Q
    Brain Tumor Pathol; 2021 Jan; 38(1):50-58. PubMed ID: 33079297
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of high-resolution melting analysis for the detection of the MYD88 L265P mutation.
    Wang CZ; Lin J; Qian J; Shao R; Xue D; Qian W; Xiao GF; Deng ZQ; Yang J; Li Y; Chen XX
    Clin Biochem; 2013 Mar; 46(4-5):385-7. PubMed ID: 23178471
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Frequent MYD88 L265P and CD79B Mutations in Primary Breast Diffuse Large B-Cell Lymphoma.
    Taniguchi K; Takata K; Chuang SS; Miyata-Takata T; Sato Y; Satou A; Hashimoto Y; Tamura M; Nagakita K; Ohnishi N; Noujima-Harada M; Tabata T; Kikuti YY; Maeda Y; Nakamura N; Tanimoto M; Yoshino T
    Am J Surg Pathol; 2016 Mar; 40(3):324-34. PubMed ID: 26752547
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Relationship between Polymorphism of miR-155 and Its Target Gene MyD88 and Clinicopathological Features of Diffuse Large B-cell Lymphoma].
    Li Y; Jia ZW; Kong XY; Cui GR; Liu XY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Jun; 29(3):757-762. PubMed ID: 34105469
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oncogenically active MYD88 mutations in human lymphoma.
    Ngo VN; Young RM; Schmitz R; Jhavar S; Xiao W; Lim KH; Kohlhammer H; Xu W; Yang Y; Zhao H; Shaffer AL; Romesser P; Wright G; Powell J; Rosenwald A; Muller-Hermelink HK; Ott G; Gascoyne RD; Connors JM; Rimsza LM; Campo E; Jaffe ES; Delabie J; Smeland EB; Fisher RI; Braziel RM; Tubbs RR; Cook JR; Weisenburger DD; Chan WC; Staudt LM
    Nature; 2011 Feb; 470(7332):115-9. PubMed ID: 21179087
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Characteristics of PD-L1 expression in tumor cells and tumor microenvironment of DLBCL with MYD88 L265P mutation].
    Fu YL; Xue XM; Shen GH; Yuan LJ; Zheng B; Zhang HF; Qiu T; Huang WT
    Zhonghua Bing Li Xue Za Zhi; 2021 Jul; 50(7):751-755. PubMed ID: 34405609
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.